QGEN - QIAGEN N.V.

47.65
-1.180   -2.476%

Share volume: 1,755,793
Last Updated: 03-03-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.31%

PREVIOUS CLOSE
CHG
CHG%
$48.83
-1.18
-0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
24%
Profitability 28%
Dept financing 16%
Liquidity 37%
Performance 19%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-4.32%
1 Month
-7.85%
3 Months
1.21%
6 Months
1.30%
1 Year
25.99%
2 Year
8.42%
Key data
Stock price
$47.65
P/E Ratio 
143.49
DAY RANGE
$46.87 - $48.08
EPS 
$1.95
52 WEEK RANGE
$38.13 - $57.82
52 WEEK CHANGE
$23.61
MARKET CAP 
10.431 B
YIELD 
N/A
SHARES OUTSTANDING 
228.203 M
DIVIDEND
$2.29
EX-DIVIDEND DATE
01-08-2026
NEXT EARNINGS DATE
07-30-2025
BETA 
0.55
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,769,715
AVERAGE 30 VOLUME 
$2,161,676
Company detail
CEO: Thierry Bernard
Region: US
Website: qiagen.com
Employees: 6,030
IPO year: 1996
Issue type: Common Stock
Market: NYSE
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring.

Recent news